Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus

References

• Stratmann B, Tschöpe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005; 2: 16–23
   PubMedGoogle Scholar
• Vaidyula V R, Rao A K, Mozzoli M, Homo C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202–208
   PubMed Web of Science ®Google Scholar
• Banga J D. Coagulation and fibrinolysis in diabetes. Semin Vasc Med 2002; 2: 75–86
   PubMedGoogle Scholar
• Vigilance J E, Reid H L. Glycaemic control influences peripheral blood flow and haemorrhagial variables in patients with diabetes. Clin Hemorheol Microcirc 2005; 33: 337–346
   PubMed Web of Science ®Google Scholar
• Tahbaz F, Kreis I, Calvert D. An audit of diabetes control, dietary management and quality of life in adults with type diabetes mellitus, and a comparison with nondiabetic subjects. J Hum Nutr Diet 2006; 19: 3–11
   PubMed Web of Science ®Google Scholar
• Coppola G, Corrado E, Muratori I, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006; 106: 16–20
   PubMed Web of Science ®Google Scholar
• Tracy R P, Arnold A M, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 1776–1783
   PubMed Web of Science ®Google Scholar
• Sherwood O D. Relaxin's physiological roles and other diverse actions. Endocr Rev 2004; 25: 205–234
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Richter C, Bartsch C, Laule M, Armbruster F P, Baumann G, Stangl K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J 2001; 15: 2187–2195
   PubMed Web of Science ®Google Scholar
• Wilson B C, Milne P, Saleh T M. Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion. Ann N Y Acad Sci 2005; 1041: 223–238
   PubMed Web of Science ®Google Scholar
• Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann N Y Acad Sci 2005; 1041: 441–443
   PubMed Web of Science ®Google Scholar
• Perna A M, Masini E, Nistri S, Briganti V, Chiappini L, Stefano P, Bigazzi M, Pieroni C, Bani Sacchi T, Bani D. Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J 2005; 19: 1525–1527
   PubMed Web of Science ®Google Scholar
• Bacchari M C, Calami F. Relaxin: new functions for an old peptide. Curr Protein Pept Sci 2004; 5: 9–18
   PubMed Web of Science ®Google Scholar
• Failli P, Nistri S, Mazzetti L, Chiapini L, Bani D. Effects of relaxin on vascular smooth muscle and endothelial cells in normotensive and hypertensive rats. Ann N Y Acad Sci 2005; 1041: 311–313
   PubMed Web of Science ®Google Scholar
• Cohen R A. Role of nitric oxide in diabetic complications. Am J Ther 2005; 12: 499–502
   PubMedGoogle Scholar
• Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925–1931
   PubMed Web of Science ®Google Scholar
• Langenfeld M R, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert S D, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525–2531
   PubMed Web of Science ®Google Scholar
• Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner A H, Kann P, Forst T. Pioneer Study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005; 37: 510–515
   PubMed Web of Science ®Google Scholar
• Concannon P W, Gimpel T, Newton L, Castrace V D. Postimplantation increase in plasma fibrinogen concentration with increase in relaxin concentration in pregnant dogs. Am J Vet Res 1996; 57: 1382–1385
   PubMed Web of Science ®Google Scholar
• Concannon P, Tsutsui T, Shille V. Embryo development, hormonal requirements and maternal responses during canine pregnancy. J Reprod Fertil Suppl 2001; 57: 169–179
   PubMedGoogle Scholar
• Nasr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol Endocrinol 1998; 12: 43–59
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005; 28: 2472–2479
   PubMed Web of Science ®Google Scholar
• Tracy R P. Atherogenesis and coronary heart disease. International textbook of diabetes mellitus3rd ed, R A DeFronzo, E Ferrannini, H Keen, P Zimmet. Wiley, ChichesterUK 2004; 1437–1447
   Google Scholar
• Moore X L, Tan S L, Lo C Y, Fang L, Su Y D, Gao X M, Woodcock E A, Summers R J, Tregear G W, Bathgate R A, et al. Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 2007; 148: 1582–1589
   PubMed Web of Science ®Google Scholar
• Lekgabe E D, Royce S G, Hewitson T D, Tang M L, Zhao C, Moore X L, Tregear G W, Bathgate R A, Du X J, Samuel C S. The effects of relaxin and estrogen deficiency on collagens and hypertrophy on nonreproductive organs. Endocrinology 2006; 147: 5575–5583
   PubMed Web of Science ®Google Scholar
• Sarafidis P A, Lasaridis A N, Nilsson P M, Mouslech T F, Hitoglou-Makedou A D, Stafylas P C, Kazakos K A, Yovos J G, Tourkantonis A A. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005; 54: 1236–1242
   PubMed Web of Science ®Google Scholar
• Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharmaceut Design 2005; 11: 2331–2365
   PubMed Web of Science ®Google Scholar
• Tan K T, Tayebjee M H, Lim H S, Lip G Y. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med 2005; 22: 1657–1662
   PubMed Web of Science ®Google Scholar
• Schneider D J, Keating F K, Baumann P Q, Whitaker D A, Sobel B E. Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus. Coron Artery Dis 2006; 17: 57–61
   PubMed Web of Science ®Google Scholar